NCT07530003 HUMSCs Combined With Col I to Third-Degree Burn Wound
| NCT ID | NCT07530003 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | The First Affiliated Hospital of Xinxiang Medical College |
| Condition | Burn Wounds |
| Study Type | INTERVENTIONAL |
| Enrollment | 108 participants |
| Start Date | 2026-04-06 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 108 participants in total. It began in 2026-04-06 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the safety and tolerability of human umbilical cord mesenchymal stem cells combined with bovine type I collagen in the treatment of third-degree burn wounds.
Eligibility Criteria
Inclusion Criteria: * Aged 18-65 years, gender unrestricted * Confirmed third-degree burns, wound area 1%-5% TBSA * Admission within 72 hours after burn injury * Voluntarily signed informed consent * Able to cooperate and complete follow-up Exclusion Criteria: * Pregnant or lactating females * Severe immunodeficiency or autoimmune disease * History of malignant tumor, or coagulation dysfunction * Severe cardiac, hepatic, or renal insufficiency * Hypersensitivity to collagen or stem cell components * Uncontrollable severe wound infection * Participation in other clinical studies within the past 3 months * Inability to comply with follow-up
Contact & Investigator
Wenjie Ren
PRINCIPAL INVESTIGATOR
The First Affiliated Hospital of Xinxiang Medical College
Frequently Asked Questions
Who can join the NCT07530003 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Burn Wounds. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07530003 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07530003 currently recruiting?
Yes, NCT07530003 is actively recruiting participants. Contact the research team at 13937354075@163.com for enrollment information.
Where is the NCT07530003 trial being conducted?
This trial is being conducted at Xinxiang, China.
Who is sponsoring the NCT07530003 clinical trial?
NCT07530003 is sponsored by The First Affiliated Hospital of Xinxiang Medical College. The principal investigator is Wenjie Ren at The First Affiliated Hospital of Xinxiang Medical College. The trial plans to enroll 108 participants.